CN103800661B - A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation - Google Patents
A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation Download PDFInfo
- Publication number
- CN103800661B CN103800661B CN201410012306.9A CN201410012306A CN103800661B CN 103800661 B CN103800661 B CN 103800661B CN 201410012306 A CN201410012306 A CN 201410012306A CN 103800661 B CN103800661 B CN 103800661B
- Authority
- CN
- China
- Prior art keywords
- extract
- compositions
- group
- mice
- fructus lycii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation, described compositions contains following component: cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract.Through experiment display: compositions avirulence provided by the invention, there is the function of enhancing immunity, alleviating physical fatigue.
Description
Technical field
The present invention relates to field of health care food, specifically a kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation.
Background technology
Immunity is body identification and eliminating antigenicity foreign body, safeguards the physiological equilibrium of self and stable a kind of function, i.e. defence, certainly steady and supervision three zones.The immunologic function of body is to produce in long-term biological evolution process.Immunne response carries out in body immune system, and immune system is made up of immune organ, immunocyte and immune molecule, is performed by innate immunity (nonspecific immunity) and acquired immunity (specific immunity) respectively.Wherein acquired immunity is completed by cellular immunity and humoral immune close fit.Therefore, raising immunity and resisting fatigue also become the focus of growing interest, and the health food that exploitation is function with enhancing immunity and alleviating physical fatigue just has vast meaning.
Patient or immunologic hypofunction suffer virus infraction, or dysimmunity produces allergy allergy, or immunologic derangement produces autoimmune.Modern medicine is in the mechanism and diagnosis of above-mentioned disease, and there is a profound understanding and various detection meanss, but still stays in " primary stage " in the treatment of disease, and adjustment and recovery to immunologic function lack effective means and medicine.Many patients have no alternative but to rely on hormone to subsist, because prolonged application hormone side effect layer goes out constantly, has endless trouble.
Pertinacious disease obstinate disease is early recognized by ancients, and " immunity " word has elaboration all through the ages in Chinese medical book.As its name suggests, namely immunity exempts the evil of epidemic disease.The traditional Chinese medical science is thought: " persistent ailment system expectorant ", and expectorant i.e. sick prefix next one inflammation word, and dysimmunity causes that morbid state inflammation is the common trait of above-mentioned persistent ailment.Therefore Chinese medicine method in treatment immune disease is a lot of, and curative effect is rather good.Such as some heat and toxic materials clearing away medicine energy antiviral and infection, some drug for invigorating blood circulation and eliminating stasis energy antiallergic and elimination allergy, the immunologic function of some medicine energy enhancing body of tonifying Qi of the kidney, immunity can also be two-ways regulation by some Chinese medicine, make T lymphocytosis, bone-marrow-derived lymphocyte reduces, and some Chinese medicine can also regulate and control complement and various lymphokine.In a word, grasp Chinese and western medical science theoretical, flexible Application Chinese medicine, on the stubborn disease treating various dysimmunities, tend to obtain and treat better effect than simple western medicine.
About the compositions of enhancing immunity, there is a lot of report:
CN201010532968.0(publication number is CN102465073A) disclose a kind of Fig health care wine, utilizing the compositions of the compositions such as Fructus Fici, Fructus Jujubae, Fructus Lycii, cervus elaphus linnaeus, Radix Ginseng, Herba Epimedii, Ganoderma, Mel, the party has the effect of enhancing immunity.
CN201110138602.X(publication number is CN102204995A) disclose the Traditional Chinese medicinal health-care wine of a kind of invigrating kidney, it is made up of cervus elaphus linnaeus 0.4-0.5 gram, Radix Ginseng 25.0-30.0 gram, Ganoderma 14.0-15.0 gram, Herba Epimedii 20.0-22.0 gram, 4.0-5.0 gram of Poria, Fructus Lycii 25.0-30.0 gram, medical material.
At present, there is not yet the novel composing prescription of cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract composition.
Summary of the invention
It is an object of the invention to provide the compositions of a kind of enhancing immunity, alleviating physical fatigue.
A kind of enhancing immunity provided by the invention, alleviating physical fatigue compositions, it contains following component: cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract.
Concrete, described compositions contains the composition of following weight portion: cervus elaphus linnaeus 1-4 part, Fructus Lycii extract 0.5-3 part, Radix Ophiopogonis extract 0.5-2 part, Ganoderma extract 0.5-2 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
Preferably, described compositions contains the composition of following weight portion: cervus elaphus linnaeus 1.1-3.3 part, Fructus Lycii extract 0.8-2.4 part, Radix Ophiopogonis extract 0.6-1.8 part, Ganoderma extract 0.55-1.65 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
It is preferred that, described compositions contains the composition of following weight portion: cervus elaphus linnaeus 2.2 parts, Fructus Lycii extract 1.6 parts, Radix Ophiopogonis extract 1.2 parts, Ganoderma extract 1.1 parts, Radix Panacis Quinquefolii extract 1 part.
In above-mentioned composition:
Described weight portion can be the known unit of weights of field of medicaments such as μ g, mg, g, kg, it is also possible to is its multiple, such as 1/10,1/100,10 times, 100 times etc.；
Described Fructus Lycii extract refers to the water extract of Fructus Lycii, and wherein the content of crude polysaccharides is no less than 30.0%；
Described Radix Ophiopogonis extract refers to the water extract of Radix Ophiopogonis, and the content of crude polysaccharides is no less than 3.0%；
Described Ganoderma extract refers to the water extract of Ganoderma, and the content of crude polysaccharides is no less than 10.0%；
Described Radix Panacis Quinquefolii extract refers to the ethanol extract of Radix Panacis Quinquefolii, and the content of total saponins is no less than 10.0%.
Present invention also offers the preparation containing above-mentioned composition, said preparation is made up of compositions and pharmaceutically acceptable carrier.
Concrete, in described preparation: compositions 6-8 part and pharmaceutically acceptable carrier 0.5-5.2 part.
Preferably, in described preparation: compositions 6-8 part, microcrystalline Cellulose 0.9-2.7 part, magnesium stearate 0.04-0.12 part.
It is preferred that, in described preparation: compositions 6-8 part, microcrystalline Cellulose 1.8 parts, magnesium stearate 0.08 part.
Described preparation is tablet, capsule, granule.
In described compositions or preparation, containing following effective ingredient composition: every 100g is containing crude polysaccharides 6.3g, total saponins 1.3g.
The preparation method that present invention also offers above-mentioned preparation, the method comprises the following steps: sieved respectively by described each composition, then according to proportioning weighs each composition, mixing, conventionally formulation method prepares into preparation.
Present invention also offers the application in preparing enhancing immunity, the medicine of alleviating physical fatigue or health product of above-mentioned composition or preparation.
Enhancing immunity provided by the invention, alleviating physical fatigue compositions have following a little:
1, product provided by the invention is natural health care, according to the Traditional Chinese medical theory Therapeutic Principle to hypoimmunity and physical fatigue, and in conjunction with substantial amounts of function document and clinical literature, screen the raw material of Chinese medicine with enhancing immunity and alleviating physical fatigue, with cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract and Radix Panacis Quinquefolii extract for primary raw material.Wherein cervus elaphus linnaeus returns liver, kidney channel, invigorating kidney-YANG, benefiting essence-blood, bone and muscle strengthening；Fructus Lycii returns liver, kidney channel, can nourishing the liver and kidney, benefit essence hemopoietic, improving eyesight；Radix Ophiopogonis GUIXIN, lung, stomach, can YIN nourishing and the production of body fluid promoting, lung moistening clear away heart-fire.Ganoderma GUIXIN, lung, liver, kidney channel, can invigorating QI and tranquilization, relieving cough and asthma；Radix Panacis Quinquefolii GUIXIN, lung, kidney channel, can boosting qi and nourishing yin, clearing away heat and promoting production of body fluid；All medicines share, can the liver and the kidney tonifying, lung moistening clears away heart-fire, QI invigorating is supporing yang, replenishing YIN and removing heat, nourishing blood to tranquillize the mind.Hit hypoimmunity and physical fatigue patients blood, body fluid loss, the etiology and pathogenesis of visceral dysfunction, promotes that the mediation of equilibrium between yin and yang, QI and blood, function are coordinated, reaches effect of alleviating physical fatigue and enhancing immunity.And persistent, raw material sources are extensive, the material benefit of reliable in quality, price.
2, this product is raw materials used is safe healthy food material, and production technology meets food hygiene related request, therefore this product edible safety, without any side effects, can eat for a long time.
3, consumption aspect, this product is raw materials used is all Ministry of Public Health, State Food and Drug Administration approves spendable healthy food material, the requirement of the Primary Reference Pharmacopoeia of the People's Republic of China and relevant policies regulation on consumption, Chinese Pharmacopoeia records consumption primarily as treatment consumption, should not as the effective guarantee of the function of health food with safety, and pharmacopeia consumption can be understood as single medicinal material consumption, and the traditional tcm health preserving of the many utilizations of health food prescription is theoretical and experience, composite make, adding medicine is that short-term is for therapeutic use, and health food is to select voluntarily for a long time to eat, therefore the consumption of each raw material accordingly also can be on the low side.The each raw material of this product is without incompatibility.Each raw material dosage also embodies its safer one side lower than pharmacopeia consumption.
4, through experiment display: compositions avirulence provided by the invention, there is the function of enhancing immunity, alleviating physical fatigue.
Detailed description of the invention
Following example are used for illustrating the present invention, but are not limited to the scope of the present invention.
Described Fructus Lycii extract refers to the water extract of Fructus Lycii, and wherein the content of crude polysaccharides is no less than 30.0%, purchased from Jia Kang source, Beijing development in science and technology company limited；
Described Radix Ophiopogonis extract refers to the water extract of Radix Ophiopogonis, and the content of crude polysaccharides is no less than 3.0%, purchased from Jia Kang source, Beijing development in science and technology company limited；
Described Ganoderma extract refers to the water extract of Ganoderma, and the content of crude polysaccharides is no less than 10.0%, purchased from Jia Kang source, Beijing development in science and technology company limited；
Described Radix Panacis Quinquefolii extract refers to the ethanol extract of Radix Panacis Quinquefolii, and the content of total saponins is no less than 10.0%, purchased from Jilin Hongjiu Biotech Co., Ltd..
Embodiment 1: enhancing immunity, alleviating physical fatigue compositions
1, formula: cervus elaphus linnaeus 55g, Fructus Lycii extract 120g, Radix Ophiopogonis extract 90g, Ganoderma extract 27.5g, Radix Panacis Quinquefolii extract 25g.
Adjuvant: microcrystalline Cellulose 182g, magnesium stearate 2g.
2, preparation method:
1) get the raw materials ready: cervus elaphus linnaeus adopts60Co roentgenization carries out irradiation sterilization (5KGy), standby；
2) pulverize, sieve: 80 mesh sieves are pulverized and crossed to the cervus elaphus linnaeus Universalpulverizer after irradiation sterilization, standby；
Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate cross 80 mesh sieves in vortex oscillation is sieved, standby.
3) weigh, mix: weigh cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate by formula ratio, put in mixer and mix 30 minutes, mix homogeneously, obtain mixed powder.
4) fill capsule, select capsule, polishing, subpackage: mixed powder automatic hard capsule filler fills capsule.Adjusting and filling loading amount is 0.45g/ grain.After medicine buffing machine polishes, it is distributed into plastic bottle in bottled production line；
5) outer package, product inspection and warehouse-in.
Embodiment 2: enhancing immunity, alleviating physical fatigue compositions
1, formula: cervus elaphus linnaeus 165g, Fructus Lycii extract 40g, Radix Ophiopogonis extract 30g, Ganoderma extract 82.5g, Radix Panacis Quinquefolii extract 75g.
Adjuvant: microcrystalline Cellulose 45g, magnesium stearate 6g.
2, preparation method:
1) get the raw materials ready: cervus elaphus linnaeus adopts60Co roentgenization carries out irradiation sterilization (5KGy), standby.
2) pulverize, sieve: 80 mesh sieves are pulverized and crossed to the cervus elaphus linnaeus Universalpulverizer after irradiation sterilization, standby.Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate cross 80 mesh sieves in vortex oscillation is sieved, standby.
3) weigh, mix: weigh cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate by formula ratio, put in mixer and mix 30 minutes, mix homogeneously, obtain mixed powder；
4) fill capsule, select capsule, polishing, subpackage: mixed powder automatic hard capsule filler fills capsule.Adjusting and filling loading amount is 0.45g/ grain.After medicine buffing machine polishes, it is distributed into plastic bottle in bottled production line；
5) outer package, product inspection and warehouse-in.
Embodiment 3: enhancing immunity, alleviating physical fatigue compositions
1, formula: cervus elaphus linnaeus 110g, Fructus Lycii extract 80g, Radix Ophiopogonis extract 60g, Ganoderma extract 55g, Radix Panacis Quinquefolii extract 50g.
Adjuvant: microcrystalline Cellulose 120g, sucrose 100g, PVP K30 20g, magnesium stearate 5g, coating powder 15g.
2, preparation method
1) get the raw materials ready: cervus elaphus linnaeus adopts60Co roentgenization carries out irradiation sterilization (5KGy), standby.
2) pulverize, sieve: 80 mesh sieves are pulverized and crossed to cervus elaphus linnaeus and sucrose respectively with pulverizer, standby；Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate cross 80 mesh sieves in vortex oscillation is sieved, standby；
3) weigh, mix: weigh cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, sucrose, PVP K30, magnesium stearate, coating powder according to formula ratio respectively, cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, sucrose are put in mixer and mixed 30 minutes, mix homogeneously, obtains mixed powder.
4) granulate, dry, granulate, always mix: PVP K30 adds 95% ethanol, and to be made into concentration be 15%(volume ratio) PVP K30 alcoholic solution; and join in the mixed powder that step 3) obtains; soft material processed in wet granulator; soft material is granulated with 18 mesh sieves; obtain wet granular; wet granular is placed in fluidized drying pelletizer dry (temperature 45～50 DEG C), then with Fast granulate machine 16 mesh sieve granulate, obtains dry granule.It is placed in mixer by dry granule with magnesium stearate to mix 5 minutes, obtains always mixed granule.
5) tabletting: total mixed granule tabletting machine, 0.6g/ sheet, obtains plain sheet.Check, reject defective.
6) coating: film coating procedure
Coating powder is slowly added in 70% ethanol prepared, stirs, cross 100 mesh sieves standby.Solid-liquid w/v g:ml is 1:12.5.Open seed-coating machine, add element sheet, be preheating to 40 DEG C, adjust rotating speed and be 3-4 rev/min, adjustable spraying amount, control air output, pressure and inlet temperature at any time, after thin film dress material has sprayed, continue dry 20-30 minute.Dry in the air sheet.Coating weight gain 2-3%.Reject defective coated tablet；
7) inner packing: qualified coated tablet is proceeded to plastic bottle；
8) outer package, product inspection, warehouse-in.
Comparative example: compositions
Composition and preparation method, with reference to the embodiment 1 of CN201110138602.X, adopt the preparation method identical with embodiment 1, and it consists of:
Cervus elaphus linnaeus 0.48g, Radix Ginseng 28.80g, Ganoderma 14.40g, Herba Epimedii 21.60g, Poria 4.80g, Fructus Lycii 28.80g.
Experimental example 1: toxicological test
1, test objective: whether inspection product has toxicity.
2, test material:
2.1 samples: the compositions that embodiment 1 provides, people's plan dosage is 1.8g/60kg.bw. day, and institute's feeding sample is capsule 's content, for brown to the alternate powder of brown color.
2.2 laboratory animals: cleaning grade ICR mice.
2.3 experimental situation conditions: temperature 20 DEG C～25 DEG C, humidity 40～70.
3, experimental technique: adopt the chmice acute Oral toxicity test of routine, Salmonella reversion test, mouse marrow cell micro nuclear test, mouse inbred strain to check product toxicity, specifically include following experimental procedure:
3.1 chmice acute Oral toxicity tests: select cleaning grade Kunming mouse 20, body weight 18-22 gram, male and female half and half, test by MTD method (maximum tolerated dose).Weighing tested material 60g and add deionized water to 160ml mixing, employing equal-volume administration by gavage (0.2ml/10g bw) secondary gavage in 24 hours, dosage is 20ml/kg bw.Continuous Observation two weeks, record poisoning manifestations and death condition；
3.2Ames tests: adopt flat board incorporation methods, divides and adds and be not added with S-9 mixed liquor two kinds.Dosage respectively 0.008,0.040,0.200,1.000,5.000mg/ ware, separately set blank group, solvent control group (deionized water) and positive controls.
Tested material compound method is, weighs tested material 2.5g and is dissolved in 50ml deionized water, and sterilizing in 0.103Mpa20 minute is stock solution；Taking stock solution 1ml, to add sterilizing deionized water 4ml be 1.000mg/ ware dosage；5 times are diluted to other dosage successively.Take each dosage group liquid 100 μ l to add in top layer culture medium.Positive controls uses 2-AF20 μ g/ ware, 2,4,7-TNFone0.5 μ g/ wares, NaN32.5 μ g/ wares, ametycin 4.0 μ g/ ware, 1,8 dihydroxyanthraquinone 50 μ g/ ware, each dosage group makees three parallel wares, repeats to do twice.Bacterial strain is TA97(a), TA98, TA100 and TA102 four strain bacterium, S-9 consumption is every ware 0.5mlS-9 mixed liquor (containing S-950 μ l).Bacterial strain is purchased from Tianjin Center for Disease Control and Prevention, and S-9 is purchased from Occupational Health and Poisoning Control Inst., China Disease Prevention and Co, and reagent is purchased from Beijing chemical reagents corporation；
3.3 mouse marrow cell micro nuclear tests: select cleaning grade Kunming mouse 50, be randomly divided into five groups, often group 10, male and female half and half；If three dosage group: 2.5g/kg bw, 5.0g/kg bw, 10.0g/kg bw.
Tested material compound method is: weigh tested material 2.5g, 5.0g, 10.0g add respectively deionized water to 80ml mix；Set negative control group (deionized water) and positive controls (cyclophosphamide 200mg adds normal saline to 100ml, and dosage is 40mg/kg bw) simultaneously.Adopt equal-volume administration by gavage (0.2ml/10g bw), each 24 hours twice of equal interval of group provisions, after second time provisions, within 6 hours, take bone marrow of sternum film-making, every animal 1000 polychromatic erythrocytes (PCE) of counting, calculate its microkernel incidence；Count the mature erythrocyte (RBC) in 200 polychromatic erythrocyte visuals field, calculate PCE/RBC ratio
3.4 mouse inbred strain reports: select cleaning grade Kunming kind mice 25, be randomly divided into five groups, often group five；If three dosage groups: 2.5/5.0/10.0g/kg bw.
Tested material compound method is: weigh tested material 5.0,10.0,20.0g adds deionized water respectively and mixes to 160ml；Set negative control group (deionized water) and positive controls (cyclophosphamide 200mg adds normal saline to 100ml, and dosage is 40mg/kg bw) simultaneously.Adopt equal-volume administration by gavage (0.2ml/10g bw), continuous per os provisions 5 days, within the 35th day, put to death animal from provisions meter first, take bilateral epididymal film-making, every animal 1000 sperms of counting, calculate abnormal rate.
4, result of the test:
4.1 acute toxicities: female mice per os MTD is all higher than 20.0g/kg body weight by the compositions that embodiment 1 provides, and belongs to nontoxic level.
4.2 micronucleus tests: mice bone marrow micronucleus testing result is negative by the compositions that embodiment 1 provides.
4.3Ames tests: the compositions Salmonella reversion test testing result that embodiment 1 provides is negative.
4.4 mouse inbred strain: mouse inbred strain testing result is negative by the compositions that embodiment 1 provides.
Result shows: compositions provided by the invention does not have toxicity.
Experimental example 2: enhancing immunity zoopery:
1, test material:
1.1 samples: the compositions that embodiment 1 provides, people's plan dosage is 1.8g/60kg bw. day, and institute's feeding sample is capsule 's content, for brown to brownish-yellow powder.
1.2 experimental animals: 18-22g female SPF mice 192.
1.3 dosage choice and tested material give mode: basic, normal, high three the dosage groups of embodiment 1 and matched group, the medicine 0.90g/kg BW that medicine 0.15g/kg BW, 0.30g/kg BW, 0.90g/kg BW and the comparative example that respectively embodiment 1 proportioning is made is made, wherein the consumption of embodiment 1 is equivalent to 5 times of people's plan dosage, 10 times, 30 times.Tested material is prepared with sterilized water, and per os gives once a day, and continuous gavage surveys indices after 32 days, and mouse stomach volume is 0.1ml/10g Mus weight.Setting blank group (0g/kg BW) simultaneously, replace tested material with sterilized water, every day, gavage volume was identical with each tested material group.Each dosage group all gives normal feedstuff.
1.4 key instruments and reagent: electronic balance, spiral micrometer, microsyringe, 24 holes and 96 level land, hole Tissue Culture Plate plates, the 96 U-shaped Tissue Culture Plates in hole etc.
2, functional examination:
Delayed allergy: taking Sanguis caprae seu ovis, brine 3 times, through the Sanguis caprae seu ovis of lumbar injection 2%, 24h measures left back sufficient sole of the foot portion thickness after injection；
The mouse lymphocyte transformation experiment of ConA induction: aseptic take spleen, grind with tweezers, make cell suspension, microscopy counts, and cultivates, colorimetric determination on spectrophotometer；
Antibody-producting cell detects: taking Sanguis caprae seu ovis, brine 3 times, every Mus, through lumbar injection 2%, takes spleen, grinds with tweezers, makes cell suspension, counts hemolysis plaque number；
The mensuration of half hemolysis value: taking Sanguis caprae seu ovis, brine 3 times, every Mus, through lumbar injection 2%, collects serum, measures optical density value；
Mice carbonic clearance is tested: dilutes the india ink of 4 times by body weight from mouse tail vein injection, uses spectrophotometric determination；
Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell experiment: mouse peritoneal injects 20% chicken red blood cell, calculates phagocytic rate and phagocytic index；
NK cytoactive: before experiment, target cell is carried out Secondary Culture by 24h, in microplate reader densitometric value, calculates NK cytoactive.
3, result of the test:
3.1 impacts on mice delayed allergy (DTH): in Table 1
Table 1: the impact on mice delayed allergy (DTH)
| Group | Dosage | Number of animals (only) | Swelling degree of the paw (mm) |
| Blank group | 0g/kg·BW | 12 | 0.44±0.08 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 0.68±0.19*# |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 0.70±0.23*# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 0.63±0.17*# |
| Contrast groups | 0.90g/kg·BW | 12 | 0.45±0.09 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 1 result shows: compared with blank group, per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, the low dose group of embodiment 1 and middle dosage group swelling degree of the paw have significant difference (P < 0.01), and high i.e. two groups of swelling degree of the paw have significant difference (P < 0.05).Compare with comparative example group, each group of embodiment 1 can in various degree improve mice delayed allergy ability (P < 0.05).
3.2 impacts on mouse lymphocyte transformation experiment: in Table 2
Table 2: the impact on mouse lymphocyte transformation experiment
| Group | Dosage | Number of animals (only) | Lymphopoiesis ability (OD difference) |
| Blank group | 0g/kg·BW | 12 | 0.26±0.08 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 0.29±0.06 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 0.32±0.10 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 0.37±0.10*# |
| Contrast groups | 0.90g/kg·BW | 12 | 0.25±0.06 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 2 result shows: per os gave compositions embodiment 1 medicine of embodiment 1 offer of mice various dose after 32 days, and high dose group compares with blank group, and lymphopoiesis ability has significant difference (P < 0.05).Namely embodiment 1 high dose group all can improve mouse lymphocyte multiplication capacity.
Comparing with comparative example group, embodiment 1 high dose group of Isodose can improve mouse lymphocyte multiplication capacity.(P < 0.05)
3.3 impacts on mouse antibodies cellulation number: in Table 3
Table 3: the impact on mouse antibodies cellulation number
| Group | Dosage | Number of animals (only) | Hemolysis plaque number (× 103/ full spleen) |
| Blank group | 0g/kg·BW | 12 | 190±100 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 297±200 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 378±123*# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 354±200*# |
| Contrast groups | 0.90g/kg·BW | 12 | 300±128 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 3 result shows: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, and compared with blank group, middle dosage group and high dose group antibody-producting cell number have significant difference (P < 0.05).Namely the middle dosage group of embodiment 1 and high dose group all can improve mouse antibodies cellulation number.
Comparing with comparative example group, embodiment 1 high dose group of Isodose can improve mouse antibodies cellulation number.(P < 0.05)
3.4 impacts on mice carbonic clearance ability: in Table 4
Table 4: the impact on mice carbonic clearance ability
| Group | Dosage | Number of animals (only) | Phagocytic index (a) |
| Blank group | 0g/kg·BW | 12 | 6.38±0.69 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 6.44±0.50 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 6.84±0.81*# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 7.13±0.86*# |
| Contrast groups | 0.90g/kg·BW | 12 | 6.40±0.68 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 4 result shows: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, and compared with blank group, the carbonic clearance phagocytic index of middle dosage group and high dose group has significant difference (P < 0.05).Namely the middle and high dosage group of embodiment 1 can improve the carbonic clearance ability of mice.
Comparing with comparative example group, embodiment 1 high dose group of Isodose can improve the carbonic clearance ability of mice.(P < 0.05)
Mouse macrophage is swallowed the impact of chicken red blood cell phagocytic rate by 3.5: in Table 5
Table 5: mouse macrophage is swallowed the impact of chicken red blood cell phagocytic rate
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 5 result shows: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, and compared with blank group, the phagocytic rate of high dose group mouse macrophage phagocytosis chicken red blood cell has significant difference (P < 0.05).Namely embodiment 1 high dose group group all can improve mouse macrophage phagocytosis chicken red blood cell phagocytic rate.
Comparing with comparative example group, embodiment 1 high dose group of Isodose can improve mouse macrophage phagocytosis chicken red blood cell phagocytic rate.(P < 0.05)
Mouse macrophage is swallowed the impact of chicken red blood cell phagocytic index by 3.6: in Table 6
Table 6: mouse macrophage is swallowed the impact of chicken red blood cell phagocytic index
| Group | Dosage | Number of animals (only) | Phagocytic index |
| Blank group | 0g/kg·BW | 12 | 0.41±0.14 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 0.42±0.11 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 0.47±0.10 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 0.54±0.09*# |
| Contrast groups | 0.90g/kg·BW | 12 | 0.45±0.12 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 6 result shows: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, and compared with blank group, the macrophage phagocytic chicken red blood cell phagocytic index of high dose group mice has significant difference (P < 0.05).Namely embodiment 1 high dose group can improve mouse macrophage phagocytosis chicken red blood cell phagocytic index.
Comparing with comparative example group, embodiment 1 high dose group of Isodose can improve mouse macrophage phagocytosis chicken red blood cell phagocytic index.(P < 0.05)
Sum up: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, compared with blank group, and this tested material low dose group can improve mice delayed allergy ability (P < 0.01)；Middle dosage group can improve Mice Mice delayed allergy ability (P < 0.01), improves the antibody-producting cell number (P < 0.05) of mice；High dose group group can improve mice delayed allergy ability (P < 0.05), improve the lymphopoiesis ability (P < 0.05) of mice, improve the antibody-producting cell number (P < 0.05) of mice, improve the carbonic clearance ability (P < 0.05) of mice, improve mouse macrophage phagocytosis chicken red blood cell phagocytic rate (P < 0.05) and phagocytic index (P < 0.05).
In like manner, to the present invention other embodiment and proportioning test, effect is with embodiment 1.
Result shows: Mouse Weight growth is had no adverse effects by tested material.
According to " health food inspection with assessment technique specification " (2003 editions), to the criterion of enhancing immunity health food it can be seen that the function results of animal of compositions enhancing immunity provided by the invention is positive.
Experimental example 3: alleviating physical fatigue function:
1, test material:
1.1 samples: the compositions that embodiment 1 provides, people's plan dosage is 1.8g/60kg bw. day, and institute's feeding sample is capsule 's content, for brown to brownish-yellow powder.
The male SPF level mice of 1.2 experimental animals: 18-22g 204.
1.3 dosage choice and tested material give mode: basic, normal, high three the dosage groups of embodiment 1, respectively 0.15g/kg BW, 0.30g/kg BW, 0.90g/kg BW, be namely equivalent to 5 times of people's plan dosage, 10 times, 30 times.Tested material is prepared with sterilized water, and per os gives once a day, and continuous gavage surveys indices after 32 days, and mouse stomach volume is 0.1ml/10g Mus weight.Setting a blank group (0g/kg BW) simultaneously, replace tested material with sterilized water, every day, gavage volume was identical with each tested material group.Each dosage group all gives normal feedstuff.
1.4 key instruments and reagent: 755 spectrophotometers, Plasma lactate instrument, biochemistry analyzer, electronic balance, centrifuge, agitator, swimming trunk, galvanized wire, sample injector, homogenizer, test tube, tool plug test tube.
2, test method: functional examination
Tested by swimming with a load attached to the body: mice load 5% body weight galvanized wire is placed in swimming trunk went swimming, and record mice starts to the dead time from swimming；
Serum urea: last is to after mice tested material, and eyeball blood sampling is pulled out in swimming after having a rest, measure in biochemistry analyzer；
Hepatic glycogen: last, to after mice tested material, is put to death immediately, takes liver filter paper after normal saline rinses and blots, measure;
The mensuration of blood lactase acid: last is to after mice tested material, and blood sampling, swimming, rest, by Plasma lactate instrument mensuration.
3, result of the test:
3.1 impacts on the mice burden swimming time: in Table 7
Table 7: the impact on the mice burden swimming time
| Group | Dosage | Number of animals (only) | During swimming with a load attached to the body (min) |
| Blank group | 0g/kg·BW | 15 | 4.5±2.0 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 15 | 6.6±2.8 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 15 | 7.0±3.0 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 15 | 9.8±3.9*# |
| Contrast groups | 0.90g/kg·BW | 15 | 7.5±2.6 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
From table 7, per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, compared with blank group, and there is significant difference (P < 0.01) the high dose group mice burden swimming time.Namely embodiment 1 high dose group group can extend the walking weight load of mice.
Comparing with comparative example group, the embodiment 1 high dose group walking weight load of Isodose has significant difference (P < 0.01).
3.2 impacts on the mice burden swimming time: in Table 8
Table 8: on the impact of serum urea level after mice
| Group | Dosage | Number of animals (only) | Serum urea (mmol/) |
| Blank group | 0g/kg·BW | 12 | 17.7±2.3 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 16.6±2.4 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 15.8±1.5 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 15.4±1.8*# |
| Contrast groups | 0.90g/kg·BW | 12 | 16.2±2.5 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
From table 8, per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, compared with blank group, and the serum urea content of high dose group mice has significant difference (P < 0.05).Namely embodiment 1 high dose group can reduce tired mice serum urea content.
Comparing with comparative example group, the embodiment 1 high dose group serum urea content of Isodose has significant difference (P < 0.05).
3.3 impacts on the mice burden swimming time: in Table 9
Table 9: the impact on Mouse Liver glycogen content
| Group | Dosage | Number of animals (only) | Hepatic glycogen (mg/100g liver) |
| Blank group | 0g/kg·BW | 12 | 4879±913 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 6383±616*# |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 6451±525*# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 4845±478# |
| Contrast groups | 0.90g/kg·BW | 12 | 4915±547 |
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 9 result shows: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, and compared with blank group, the hepatic glycogen content of dosage group mice low, middle has significant difference (P < 0.01).Namely embodiment 1 dosage group low, middle can increase tired Mouse Liver glycogen content.
Comparing with comparative example group, the embodiment 1 high dose group hepatic glycogen content of Isodose has significant difference (P < 0.01).
3.4 impacts on the mice burden swimming time: in Table 10
Table 10: the impact of blood lactase acid value after mice is swum
Note: compared with blank group,*P<0.05,**P<0.01；Compared with contrast groups,#P<0.05
Table 10 result shows: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, and blank group compares, and the blood lactase acid area under curve of high dose group mice has significant difference (P < 0.01).Namely embodiment 1 high dose group can reduce swimming after Mouse Blood lactic acid area under curve.
Comparing with comparative example group, the embodiment 1 high dose group blood lactase acid area under curve of Isodose has significant difference (P < 0.01)
Experiment brief summary: per os gave the compositions of embodiment 1 offer of mice various dose after 32 days, compared with blank group, and this tested material low dose group can improve Mouse Liver glycogen content (P < 0.01)；Middle dosage group can improve Mouse Liver glycogen content (P < 0.01)；High dose group can extend mice walking weight load (P < 0.01), reduce tired mice serum urea content (P < 0.05), can reduce swim after Mouse Blood lactic acid area under curve (P < 0.01).
In like manner, to the present invention other embodiment and proportioning test, effect is with embodiment 1.
Result shows: Mouse Weight growth is had no adverse effects by tested material.
According to " health food inspection with assessment technique specification " (2003 editions) to the criterion of health food for alleviating physical strength fatigue it can be seen that compositions provided by the invention has the function of alleviating physical fatigue.
In sum: compositions avirulence provided by the invention, there is the function of enhancing immunity, alleviating physical fatigue.
Although, above use generality explanation, detailed description of the invention and test, the present invention is described in detail, but on basis of the present invention, it is possible to it is made some modifications or improvements, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to the scope of protection of present invention.
Claims (9)
1. the compositions of an enhancing immunity, alleviating physical fatigue, it is characterized in that, described compositions is grouped into by the one-tenth of following weight portion: cervus elaphus linnaeus 1-4 part, Fructus Lycii extract 0.5-3 part, Radix Ophiopogonis extract 0.5-2 part, Ganoderma extract 0.5-2 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
2. compositions according to claim 1, it is characterized in that, described compositions is grouped into by the one-tenth of following weight portion: cervus elaphus linnaeus 1.1-3.3 part, Fructus Lycii extract 0.8-2.4 part, Radix Ophiopogonis extract 0.6-1.8 part, Ganoderma extract 0.55-1.65 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
3. compositions according to claim 1, it is characterised in that described compositions is grouped into by the one-tenth of following weight portion: cervus elaphus linnaeus 2.2 parts, Fructus Lycii extract 1.6 parts, Radix Ophiopogonis extract 1.2 parts, Ganoderma extract 1.1 parts, Radix Panacis Quinquefolii extract 1 part.
4. the compositions according to any one of claim 1-3, it is characterised in that described Fructus Lycii extract refers to the water extract of Fructus Lycii, and wherein the content of crude polysaccharides is no less than 30.0%.
5. the compositions according to any one of claim 1-3, it is characterised in that described Radix Ophiopogonis extract refers to the water extract of Radix Ophiopogonis, and the content of crude polysaccharides is no less than 3.0%.
6. the compositions according to any one of claim 1-3, it is characterised in that described Ganoderma extract refers to the water extract of Ganoderma, and the content of crude polysaccharides is no less than 10.0%.
7. the compositions according to any one of claim 1-3, it is characterised in that described Radix Panacis Quinquefolii extract refers to the ethanol extract of Radix Panacis Quinquefolii, and the content of total saponins is no less than 10.0%.
8. containing the preparation of the compositions described in any one of claim 1-7, it is characterised in that said preparation is made up of compositions and pharmaceutically acceptable carrier.
9. compositions described in any one of claim 1-7 or preparation described in claim 8 application in preparing enhancing immunity, the medicine of alleviating physical fatigue or health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410012306.9A CN103800661B (en) | 2014-01-10 | 2014-01-10 | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410012306.9A CN103800661B (en) | 2014-01-10 | 2014-01-10 | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103800661A CN103800661A (en) | 2014-05-21 |
| CN103800661B true CN103800661B (en) | 2016-07-13 |
Family
ID=50698356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410012306.9A Active CN103800661B (en) | 2014-01-10 | 2014-01-10 | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103800661B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127577A (en) * | 2014-08-12 | 2014-11-05 | 安徽衡济堂灵芝产业开发有限公司 | Chinese medicine capsule for relieving physical fatigue and preparation method of Chinese medicine capsule |
| CN105341908B (en) * | 2015-11-05 | 2018-06-29 | 四川知本生物工程有限公司 | A kind of functional health-care food capsule and preparation method thereof |
| CN105663394A (en) * | 2016-02-01 | 2016-06-15 | 孙爱华 | Chinese date healthcare product having effect of enhancing immunity as well as preparation method and application of healthcare product |
| CN106138440B (en) * | 2016-08-30 | 2019-08-06 | 张丽 | A kind of composition containing maca and root of kirilow rhodiola and preparation method and purposes |
| CN106236804A (en) * | 2016-08-31 | 2016-12-21 | 山东万安药业有限公司 | A kind of Chinese medicine composition for improving body immunity |
| CN107307423A (en) * | 2017-07-12 | 2017-11-03 | 吉林青晨药业有限公司 | Product and preparation method with regulation enhancing body's immunity |
| CN107495350A (en) * | 2017-10-13 | 2017-12-22 | 延边韩工坊健康制品有限公司 | A kind of health food and preparation method with function of physical fatigue alleviation |
| CN108186879A (en) * | 2018-03-29 | 2018-06-22 | 山西正元盛邦制药有限公司 | A kind of alleviation physical fatigue Chinese medicine health-care composition and preparation method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1155401C (en) * | 2002-06-24 | 2004-06-30 | 李世臣 | Health wine for raising kidney function and immunity |
-
2014
- 2014-01-10 CN CN201410012306.9A patent/CN103800661B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103800661A (en) | 2014-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103800661B (en) | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation | |
| CN109674958A (en) | A kind of Chinese medicine composition and its preparation method and application with anti-trioxypurine | |
| US20150065452A1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| CN103169737B (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN105106816A (en) | Traditional Chinese medicine healthcare preparation with protection effect on chemical liver injury and preparing method thereof | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN104998083A (en) | Traditional Chinese medicine composition capable of improving immunity, and preparation method and applications thereof | |
| CN101391004B (en) | Medicine composition for treating late-stage esophageal carcinoma | |
| WO2017173611A1 (en) | Pharmaceutical product for treating tumor and combined immune defect, and preparation and application thereof | |
| CN106690201A (en) | Composition with immunity enhancing function and preparation method thereof | |
| CN111375035A (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN111110733B (en) | Traditional Chinese medicine composition for treating senile gouty arthritis and preparation method and application thereof | |
| CN102552377A (en) | Anti-radiation damage medicine | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN101084933A (en) | Medicinal composition for strengthening immunity and its preparing process | |
| CN104800471B (en) | It is a kind of to be used to treat Chinese medicine composition of urarthritis and its preparation method and application | |
| CN108295187A (en) | Improve the soft capsule preparation and preparation method thereof of immunity | |
| CN105770187A (en) | Health food capable of improving immunity and preparing method thereof | |
| CN102139015B (en) | Medicinal liquor capable of balancing yin and yang and improving immunity and preparation thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
| CN105770474A (en) | Lupus erythematosus resisting drug for combined immunization and preparing method and application thereof | |
| CN101073663A (en) | Chinese-medicinal composition for treating malignant tumor and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |